-
-
-
-
-
-
-
Ionis announces license agreement with Recordati for zilganersen in Alexander disease (AxD) in all countries outside the U.S.
-
-
-
-
-
-
-
Ionis reports positive zilganersen data for Alexander disease
-
-
-
-
-
-
-
Ionis announces zilganersen New Drug Application for Alexander disease (AxD) accepted by FDA for Priority Review
-
-
-
-
-
-
-
Ionis reports second quarter 2025 financial results and highlights progress on key programs
-
-
-
-
-
-
-
Ionis Pharmaceuticals (IONS) PT Lowered to $60 at Raymond James
-
-
-
-
-
-
-
RBC Capital Reiterates Outperform Rating on Ionis Pharmaceuticals (IONS)
-
-
-
-
-
-
-
Ionis reports second quarter 2023 financial results
-
15,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

